Beam Therapeutics Inc. (BEAM) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-07

Key Insights

Beam Therapeutics filed an 8-K on May 7, 2026 to announce Q1 2026 financial results for the quarter ended March 31, 2026, indicating the company is actively reporting operational performance to shareholders.
The filing is a routine earnings announcement with no material events, special disclosures, or significant corporate actions reported beyond standard financial results disclosure.
John Evans, identified as Chief Executive Officer, signed the filing, confirming continued leadership stability at the company as of the filing date.
The press release referenced in Exhibit 99.1 contains the detailed financial results but is furnished rather than filed, meaning it carries limited liability implications under securities law.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-05

Beam Therapeutics has terminated its license agreement with Bio Palette Co., Ltd., which was related to the company's base editing technology. This termination was mutual and part of Bio Palette's planned dissolution.
Prior to the termination, Beam activated a standby license agreement with Kobe University, ensuring the company maintains exclusivity over the licensed patents in the event of the Bio Palette license termination.
The termination of the Bio Palette agreement does not appear to have a significant impact on Beam's operations, as the company has secured the necessary intellectual property rights through the Kobe University standby license.

Filed: 2026-02-24

Beam Therapeutics secured a $500 million senior secured term loan facility to support the development and commercialization of its lead drug candidate, risto-cel.
The loan facility provides Beam with access to additional capital through several draw options, contingent on regulatory milestones and revenue targets for risto-cel.
The financing agreement includes covenants and restrictions on Beam's business activities, such as limits on additional debt and licensing transactions for its core intellectual property.

Filed: 2026-02-12

Beam Therapeutics has entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. to ensure continued access to certain patents in the event the existing license agreement between Bio Palette and Kobe University is terminated.
The standby license agreement provides Beam Therapeutics with an exclusive license to the patents directly from Kobe University in certain scenarios, such as a termination of the existing agreement not due to Beam's breach.
The financial terms of the standby license agreement include Beam Therapeutics paying Kobe University the amounts that would have been payable to Bio Palette under the existing license agreement.

Filed: 2026-02-05

Carole Ho, a member of Beam Therapeutics' Board of Directors, has resigned effective February 27, 2026. This change in leadership could signal a shift in the company's strategic direction or governance.
The filing does not indicate any disagreement between Carole Ho and the company regarding its operations, policies, or practices, suggesting the resignation was amicable.
As an 8-K filing, this report discloses a material event or change in the company's operations, which may be of interest to investors and analysts in evaluating Beam Therapeutics' current state and future prospects.

Other reports for Beam Therapeutics Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.